• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献>>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

乳腺癌骨转移患者溶骨性骨代谢指标与治疗效果的关系

Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases

摘要目的 探讨特异性的溶骨性骨代谢指标血I型胶原吡啶交联羧基末端肽(sICTP)、尿I型胶原吡啶交联氨基末端肽(uNTx)和尿吡啶酚(uPyd)与乳腺癌骨转移患者治疗反应的关系.方法 应用酶联免疫吸附试验(ELISA),测定120例乳腺癌患者的sICTP、uNTx和uPyd,比较其在骨转移和无骨转移患者中浓度的差别,并对乳腺癌骨转移患者进行随访,比较患者治疗前后sICTP、uNTx和aPyd指标与治疗效果的关系.结果 骨转移组患者的sICTP、uNTx和uPyd水平均明显高于无骨转移组(P<0.01),56例乳腺癌骨转移患者的sICTP、uNTx和uPyd指标间两两相关(均r>0.5,P<0.01).获得随访的45例乳腺癌骨转移患者中,临床受益组25例,sICTP、uNTx和uPyd治疗3个月后明显下降(P=0.025,P<0.001,P<0.001).病情进展组20例,治疗3个月后,sICTP、uNTx和uPyd无明显变化(P>0.05);而病情进展后,sICTP、uNTx和uPyd明显升高(P=0.011,P=0.002,P=0.002).Logistic回归分析结果显示,uPyd和uNTx治疗后降低的患者治疗收益的概率增加(OR=17.0,P=0.019;OR=16.7,P=0.015),而治疗后sICTP指标下降与治疗受益无关(P=0.841).结论 sICTP、uNTx和uPyd可作为乳腺癌骨转移患者评价疗效和转归监测的辅助指标.

更多

abstractsObjective The aim of this study was to access the relationship of osteolytic bone metabolic markers such as serum type I collagen carboxy-terminal telopeptide(sICTP),N-terminal crosslinked telopeptides of type I collagen(uNTx),urinary pyridinoline(uPyd)with the therapeutic effect in breast cancer patients with bone metastases.Methods 120 patients with breast cancer were included in thisstudy.The levels of sICTP.uNTx and uPYD were measured by ELISA assay.The differences were compared between patients with and without bone metastasis.The patients with bone metastasis were treated and foIlowed up as clinically indicated.Results The levels of all above mentioned hiomarkers in patients with bone metastasis were significantly higher than that in patients without bone metastasis(P<0.01).Asignificant correlation was found between each two markers(r>0.5,P<0.01).The biomarkers were examined again in 45 patients with bone metastasis after treatment to evaluate the treatment res;ponse.The median follow-up was 10 months.Based on clinical evaluation criteria,25 patients were responders and 20were non-responders.For responders.after 3 months treatment,the levels of the three bone markers were significantly reduced(P=0.025,P<0.001,P<0.001).But for non-respenders,with progression of bone lesions,the levels of the three nlal-kers were significantly raised(P:0.011,P=0.002,P=0.002).By means of multiple logistic regression with stepwise selection.the uPyd and uNTx activities were closely correlated with treatment response(OR=17.0,P=0.019;OR=16.7.P=0.015),however,the sICTP)did not show any correlation with treatment response P=0.841).Conclusion The levels of sICTP,uNTx and uPyd may be used as indicators in assessment of the effect of antiresorptive treatment and evaluation of prognosis in breast cancer patient with bone metastases.

More
广告
  • 浏览634
  • 下载180
中华肿瘤杂志

中华肿瘤杂志

2009年31卷12期

911-915页

MEDLINEISTICPKUCSCDCA

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷